A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Clinical trial NCT07221474 · RECRUITING
Trial details
- NCT number
- NCT07221474
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-12-12
- Primary completion
- 2029-07-02
- Enrollment
- 180
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.